Trial Profile
A multi-center, open-label trial to assess the long-term safety and efficacy of brexpiprazole as adjunctive therapy in patients with major depressive disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Sponsors Otsuka Pharmaceutical
- 29 Jun 2021 Status changed from recruiting to completed.
- 30 Jul 2018 New trial record